FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006393905> ?p ?o ?g. }

• W2006393905 endingPage "819" @default.
• W2006393905 startingPage "814" @default.
• W2006393905 abstract "Summary Relapsed/refractory myeloma has a poor outcome because of multi‐drug resistance, patient low‐performance status and toxicity of conventional chemotherapy. To improve results, standard chemotherapeutics and drugs targeting the microenvironment are applied at the same time. Bortezomib, by inhibiting proteasome function, may enhance chemosensitivity to other drugs and overcome drug‐resistance. Notably, doxorubicin and bortezomib may reciprocally increase their efficacy. Thus, to improve outcome whilst minimizing therapy‐related toxicity, liposomal doxorubicin was added to a bortezomib‐based combination. From January 2004, relapsed/refractory myeloma patients referred to our Institution received bortezomib 1·0 mg/m 2 i.v. twice weekly for 2 weeks in a 28‐d cycle for up to six cycles, oral dexamethasone 24 mg with the standard scheduling and thalidomide 100 mg continuously (VTD). From January 2005, liposomal doxorubicin, 50 mg/m 2 (30 mg/m 2 for patients older than 75 years), was added on day 4 of each cycle [VTD plus Myocet (MyVTD)]. In total, 70 patients were treated: 28 received VTD and 42 MyVTD. Baseline demographic and clinical characteristics were similar between the two groups. Toxicity was manageable although more pronounced with MyVTD. The overall response rate (81% vs. 50%, P = 0·009), time to progression (19 vs. 11 months, P = 0·01) and progression‐free survival (15 vs. 8 months, P = 0·001) were significantly higher with MyVTD regimen, suggesting an improved quality of response." @default.
• W2006393905 created "2016-06-24" @default.
• W2006393905 creator A5000684645 @default.
• W2006393905 creator A5008647277 @default.
• W2006393905 creator A5039833411 @default.
• W2006393905 creator A5065081503 @default.
• W2006393905 creator A5066243779 @default.
• W2006393905 creator A5091318797 @default.
• W2006393905 date "2008-04-22" @default.
• W2006393905 modified "2023-09-30" @default.
• W2006393905 title "The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma" @default.
• W2006393905 cites W1970309861 @default.
• W2006393905 cites W1978377409 @default.
• W2006393905 cites W2006382315 @default.
• W2006393905 cites W2017303578 @default.
• W2006393905 cites W2053723794 @default.
• W2006393905 cites W2058468326 @default.
• W2006393905 cites W2076977630 @default.
• W2006393905 cites W2091887840 @default.
• W2006393905 cites W2095328443 @default.
• W2006393905 cites W2096849250 @default.
• W2006393905 cites W2120474651 @default.
• W2006393905 cites W2124560610 @default.
• W2006393905 cites W2127760782 @default.
• W2006393905 cites W2135274807 @default.
• W2006393905 cites W2136735139 @default.
• W2006393905 cites W2141521877 @default.
• W2006393905 cites W2151924416 @default.
• W2006393905 cites W2152065071 @default.
• W2006393905 cites W2162468536 @default.
• W2006393905 cites W2166043738 @default.
• W2006393905 cites W2169295136 @default.
• W2006393905 cites W2172183914 @default.
• W2006393905 cites W2316160054 @default.
• W2006393905 doi "https://doi.org/10.1111/j.1365-2141.2008.07147.x" @default.
• W2006393905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18410447" @default.
• W2006393905 hasPublicationYear "2008" @default.
• W2006393905 type Work @default.
• W2006393905 sameAs 2006393905 @default.
• W2006393905 citedByCount "38" @default.
• W2006393905 countsByYear W20063939052012 @default.
• W2006393905 countsByYear W20063939052013 @default.
• W2006393905 countsByYear W20063939052014 @default.
• W2006393905 countsByYear W20063939052015 @default.
• W2006393905 countsByYear W20063939052018 @default.
• W2006393905 countsByYear W20063939052021 @default.
• W2006393905 crossrefType "journal-article" @default.
• W2006393905 hasAuthorship W2006393905A5000684645 @default.
• W2006393905 hasAuthorship W2006393905A5008647277 @default.
• W2006393905 hasAuthorship W2006393905A5039833411 @default.
• W2006393905 hasAuthorship W2006393905A5065081503 @default.
• W2006393905 hasAuthorship W2006393905A5066243779 @default.
• W2006393905 hasAuthorship W2006393905A5091318797 @default.
• W2006393905 hasConcept C121332964 @default.
• W2006393905 hasConcept C126322002 @default.
• W2006393905 hasConcept C142424586 @default.
• W2006393905 hasConcept C143998085 @default.
• W2006393905 hasConcept C2776364478 @default.
• W2006393905 hasConcept C2776694085 @default.
• W2006393905 hasConcept C2777478702 @default.
• W2006393905 hasConcept C2779609412 @default.
• W2006393905 hasConcept C2780401358 @default.
• W2006393905 hasConcept C2781303535 @default.
• W2006393905 hasConcept C2781413609 @default.
• W2006393905 hasConcept C29730261 @default.
• W2006393905 hasConcept C71924100 @default.
• W2006393905 hasConcept C87355193 @default.
• W2006393905 hasConcept C98274493 @default.
• W2006393905 hasConceptScore W2006393905C121332964 @default.
• W2006393905 hasConceptScore W2006393905C126322002 @default.
• W2006393905 hasConceptScore W2006393905C142424586 @default.
• W2006393905 hasConceptScore W2006393905C143998085 @default.
• W2006393905 hasConceptScore W2006393905C2776364478 @default.
• W2006393905 hasConceptScore W2006393905C2776694085 @default.
• W2006393905 hasConceptScore W2006393905C2777478702 @default.
• W2006393905 hasConceptScore W2006393905C2779609412 @default.
• W2006393905 hasConceptScore W2006393905C2780401358 @default.
• W2006393905 hasConceptScore W2006393905C2781303535 @default.
• W2006393905 hasConceptScore W2006393905C2781413609 @default.
• W2006393905 hasConceptScore W2006393905C29730261 @default.
• W2006393905 hasConceptScore W2006393905C71924100 @default.
• W2006393905 hasConceptScore W2006393905C87355193 @default.
• W2006393905 hasConceptScore W2006393905C98274493 @default.
• W2006393905 hasIssue "6" @default.
• W2006393905 hasLocation W20063939051 @default.
• W2006393905 hasLocation W20063939052 @default.
• W2006393905 hasOpenAccess W2006393905 @default.
• W2006393905 hasPrimaryLocation W20063939051 @default.
• W2006393905 hasRelatedWork W1988784378 @default.
• W2006393905 hasRelatedWork W2017303578 @default.
• W2006393905 hasRelatedWork W2142846567 @default.
• W2006393905 hasRelatedWork W2192430028 @default.
• W2006393905 hasRelatedWork W2330049167 @default.
• W2006393905 hasRelatedWork W2349567202 @default.
• W2006393905 hasRelatedWork W2515009586 @default.
• W2006393905 hasRelatedWork W2531713994 @default.
• W2006393905 hasRelatedWork W3030614660 @default.
• W2006393905 hasRelatedWork W4241469660 @default.

• next